#USA #New York #Faruqi & Faruqi #Investor Alert #Vistagen

Vistagen Therapeutics Investors: Important Class Action Lawsuit Update

A timely reminder for investors of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) as the deadline for participating in a federal securities class action suit looms near.

Key Facts about Vistagen and the Class Action

Faruqi & Faruqi, LLP, a nationally recognized securities law firm, is spearheading an investigation into potential claims against Vistagen Therapeutics. The firm is calling on investors who acquired Vistagen securities between April 1, 2024, and December 16, 2025, to discuss their options before the significant deadline on March 16, 2026. In a landscape where investor rights are paramount, this current class action could represent a vital opportunity for recovery.

The allegations against Vistagen are severe and focused on supposed violations of federal securities laws. This includes claims of misleading statements and the omission of pertinent facts related to the company's Phase 3 PALISADE-3 trial, which studies fasedienol, a prospective treatment for social anxiety disorder. The lack of transparency, as outlined in the complaint, complicates the trust investors place in the company and its leadership, prompting this legal scrutiny.

Getting Involved: The Role of the Lead Plaintiff

In class action lawsuits, class members can appoint a lead plaintiff who has the largest financial interest in the outcome of the case. This lead plaintiff plays a significant role in directing the litigation on behalf of all class members. Investors have the right to either step forward as a lead plaintiff or to remain anonymous as part of the class, ensuring that they still retain the potential for recovery.

It’s crucial for affected investors to be aware that regardless of the chosen course of action, their potential recovery in the class action is not contingent on their participation as a lead plaintiff.

Seeking Information and Whistleblower Protection

Faruqi & Faruqi encourages anyone with insights into Vistagen's dealings— including whistleblowers, former employees, and shareholders—to reach out. The firm emphasizes a safe environment for sharing information, offering confidentiality and legal protection. Engaging with legal counsel can help clarify the options available for those affected.

Next Steps for Investors

Investors can take immediate action by contacting Faruqi & Faruqi directly. Josh Wilson, a senior partner at the firm, is available for discussions regarding individual cases and implies the importance of timely communication. Interested parties can reach him at 877-247-4292 or 212-983-9330 (Ext. 1310).

Additionally, for more details about the class action, shareholders can visit Faruqi & Faruqi's website for comprehensive information.

Conclusion

As the March 16, 2026 deadline approaches, it is essential for Vistagen Therapeutics investors to be active in understanding their rights and options. Participation in the class action not only serves the interests of individual investors but also holds corporations accountable for their public disclosures and business practices. Keep an eye on this case and consider your legal rights as part of the investing community.

By staying informed and proactive, investors can navigate this complex situation with greater confidence.